Yukie Yoshii

657 total citations
35 papers, 485 citations indexed

About

Yukie Yoshii is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yukie Yoshii has authored 35 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Radiology, Nuclear Medicine and Imaging, 13 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yukie Yoshii's work include Radiopharmaceutical Chemistry and Applications (16 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Yukie Yoshii is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (16 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Yukie Yoshii collaborates with scholars based in Japan, United States and Sri Lanka. Yukie Yoshii's co-authors include Isao Inouye, Yasuhisa Fujibayashi, Atsushi B. Tsuji, Takako Furukawa, Hiroki Matsumoto, Hidekatsu Wakizaka, Tatsuya Higashi, Ming‐Rong Zhang, Takashi Maoka and Mitsuyoshi Yoshimoto and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Yukie Yoshii

32 papers receiving 477 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yukie Yoshii Japan	14	173	157	109	109	107	35	485
Bogdan I. Gerashchenko Ukraine	14	169 1.0×	196 1.2×	58 0.5×	56 0.5×	136 1.3×	42	473
Aya Sakurai Japan	12	252 1.5×	159 1.0×	156 1.4×	81 0.7×	306 2.9×	13	1.1k
Yukie Yoshii Japan	12	125 0.7×	232 1.5×	142 1.3×	233 2.1×	68 0.6×	19	633
Xiaohua Zeng China	14	39 0.2×	314 2.0×	84 0.8×	27 0.2×	27 0.3×	31	515
Xin Wei China	17	34 0.2×	317 2.0×	130 1.2×	106 1.0×	26 0.2×	36	730
Anna Maria Luciani Italy	15	122 0.7×	252 1.6×	37 0.3×	114 1.0×	43 0.4×	42	473
Nadia Ninfa Albanese Italy	16	18 0.1×	284 1.8×	62 0.6×	148 1.4×	36 0.3×	19	596
Liping Shen China	15	13 0.1×	384 2.4×	74 0.7×	188 1.7×	73 0.7×	47	619
Elvin D. de Araujo Canada	13	31 0.2×	305 1.9×	226 2.1×	37 0.3×	21 0.2×	37	495

Countries citing papers authored by Yukie Yoshii

Since Specialization

Citations

This map shows the geographic impact of Yukie Yoshii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yukie Yoshii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yukie Yoshii more than expected).

Fields of papers citing papers by Yukie Yoshii

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yukie Yoshii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yukie Yoshii. The network helps show where Yukie Yoshii may publish in the future.

Co-authorship network of co-authors of Yukie Yoshii

This figure shows the co-authorship network connecting the top 25 collaborators of Yukie Yoshii. A scholar is included among the top collaborators of Yukie Yoshii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yukie Yoshii. Yukie Yoshii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miyake, Tomohiro, Tadashi Watabe, Hiroki Kato, et al.. (2025). Preclinical evaluation of 64Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer. Breast Cancer Research. 27(1). 33–33.

Ohno, Makoto, Hiroaki Kurihara, Kimiteru Ito, et al.. (2025). Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial. Japanese Journal of Clinical Oncology. 55(5). 543–546.

Kurihara, Hiroaki, Yoshitaka Narita, Kimiteru Ito, et al.. (2024). Phase I clinical trial of ⁶⁴Cu-ATSM for malignant brain tumors.. Journal of Clinical Oncology. 42(16_suppl). 2052–2052. 1 indexed citations

Isoyama, G., Yukie Yoshii, Fukiko Hihara, et al.. (2023). An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors. International Journal of Molecular Sciences. 24(24). 17234–17234.

Hihara, Fukiko, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.. (2022). In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. International Journal of Molecular Sciences. 23(10). 5807–5807. 3 indexed citations

Matsumoto, Hiroki, Masashi Takahashi, Fukiko Hihara, et al.. (2022). Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM. Nuclear Medicine and Biology. 108-109. 10–15. 3 indexed citations

Isoyama, G., Yukie Yoshii, Fukiko Hihara, et al.. (2021). Establishment of an In Vivo Xenograft Mouse Model of a Subcutaneous Submillimeter HT-29 Tumor Formed from a Single Spheroid Transplanted Using Radiation-Crosslinked Gelatin Hydrogel Microwell. Applied Sciences. 11(15). 7031–7031. 4 indexed citations

Yoshii, Yukie, Hideaki Tashima, Yuma Iwao, et al.. (2021). Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer. Nuclear Medicine Communications. 42(10). 1112–1121. 4 indexed citations

Yoshii, Yukie, Hideaki Tashima, Yuma Iwao, et al.. (2020). Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer. Scientific Reports. 10(1). 4143–4143. 16 indexed citations

10.

Yoshii, Yukie, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.. (2019). ⁶⁴Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer. Journal of Nuclear Medicine. 60(10). 1437–1443. 26 indexed citations

11.

Yoshii, Yukie, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, et al.. (2018). Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts. Oncotarget. 9(48). 28935–28950. 20 indexed citations

12.

Jin, Zhao-Hui, Atsushi B. Tsuji, Mélissa Degardin, et al.. (2018). Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model. EJNMMI Research. 8(1). 54–54. 11 indexed citations

13.

Yoshii, Yukie, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.. (2017). Multiple Administrations of 64Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts. Translational Oncology. 11(1). 24–30. 25 indexed citations

14.

Yoshii, Yukie, Takako Furukawa, Ming-Rong Zhang, et al.. (2016). Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells. International Journal of Oncology. 48(4). 1477–1484. 9 indexed citations

15.

Furukawa, Takako, Qinghua Yuan, Yukie Yoshii, et al.. (2014). Comparison of intratumoral FDG and Cu-ATSM distributions in cancer tissue originated spheroid (CTOS) xenografts, a tumor model retaining the original tumor properties. Nuclear Medicine and Biology. 41(8). 653–659. 2 indexed citations

16.

Yoshii, Yukie, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, et al.. (2014). Controlled Administration of Penicillamine Reduces Radiation Exposure in Critical Organs during 64Cu-ATSM Internal Radiotherapy: A Novel Strategy for Liver Protection. PLoS ONE. 9(1). e86996–e86996. 23 indexed citations

17.

Yoshii, Yukie, Takako Furukawa, Nobuyuki Oyama, et al.. (2013). Fatty Acid Synthase Is a Key Target in Multiple Essential Tumor Functions of Prostate Cancer: Uptake of Radiolabeled Acetate as a Predictor of the Targeted Therapy Outcome. PLoS ONE. 8(5). e64570–e64570. 88 indexed citations

18.

Yoshida, Chisato, Chizuru Sogawa, Atsushi B. Tsuji, et al.. (2010). Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. Nuclear Medicine Communications. 31(5). 380–388. 17 indexed citations

19.

Yoshii, Yukie, Shinichi Takaichi, Takashi Maoka, & Isao Inouye. (2003). PHOTOSYNTHETIC PIGMENT COMPOSITION IN THE PRIMITIVE GREEN ALGA MESOSTIGMA VIRIDE (PRASINOPHYCEAE): PHYLOGENETIC AND EVOLUTIONARY IMPLICATIONS¹. Journal of Phycology. 39(3). 570–576. 20 indexed citations

20.

Yomota, Chikako, et al.. (1996). Separation of B-3 monodesamidoinsulin from human insulin by high-performance liquid chromatography under alkaline conditions. Journal of Chromatography A. 721(1). 89–96. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact